Fig. 1: NiVBD G-specific antibodies were isolated from a vaccinated rhesus monkey.
a Timeline of immunization (blue arrows), serum collection (magenta arrows), and PBMC isolation (green arrow). b The binding titre of the serum at each time point to the G ectodomain of NiVMY, NiVBD, and HeV was tested by ELISA. Data are average values of two replicates. c The neutralizing titres of the sera against pseudotyped rHIV-NiVMY, -NiVBD, and -HeV. Each dot represents the mean reciprocal of serum dilution at half inhibition (two replicates for rHIV-NiVMY and -HeV, and three for rHIV-NiVBD), and the value was defined as 1 (100) when half inhibition could not be achieved. d Capacity of sera to block EB2:HNV G binding in Luminex assays. Each dot represents the reciprocal of the serum dilution at half inhibition. e Sorting of single NiVBD G specific memory B-cell by flow cytometry. The gating strategies and cell proportions are indicated. f Rapid identification of NiVBD G-binding antibodies through ELISA using linear expression cassettes. The cutoff value was defined as 2.1 times the optical density of the control wells. g Phylogeny of variable genes of functional antibodies based on VDJ amino acid sequences (see also Supplementary Fig. 1a). Germline genes of neutralizing antibodies or with over four frequencies are specially marked. h Germline identity and CDRH3 sequence of eight neutralizing antibodies. i Competition-binding assay data determined by BLI (see also Supplementary Fig. 2a). Numbers in boxes indicate the percent binding of the second mAb in the presence of the first mAb compared to binding of the second mAb alone. The binding competition was determined based on the percent binding value: <33.3%, strong competition (blue boxes); 33.3–66.7%, intermediate competition (gray boxes); >66.7%, noncompetition (white boxes). Inferred competition-binding groups A to C are framed with green, magenta, and blue, respectively. Source data are provided as a Source Data file.
